theMednetRegister
  • Community
    • Overview
    • Experts
    • Editors
    • Fellows
    • Code of conduct
    • AI Guidelines for Physicians
  • Company
    • About Us
    • FAQs
    • Privacy Policy
    • Terms of Use
    • Careers
    • Programs
  • News
    • News Releases
    • Press Coverage
    • Publications
    • Blog
  • Contact Us
  • Sign in

Nephrology

NCI-CCC Tumor Board Question   

These are questions being discussed by academics at NCI-Cancer Centers

Questions discussed in this category


How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?
Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.
1 Answer available
21041


Papers discussed in this category


Kidney international, 2018-07
Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.

BMC nephrology, 2019-02-14
Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.

Related Topics in Nephrology

  • Hematologic Malignancies
  • Radiation Oncology
  • Gynecologic Oncology
  • Genitourinary Cancers
  • Melanoma/Skin Cancer
  • Pediatric Hematology/Oncology
  • Prostate Cancer
  • Medical Oncology
  • Endocrine Tumors
  • Lymphoma

Copyright © 2025 theMednet
All Rights Reserved.